INO Inovio Pharmaceuticals
- 5.1700
- +0.0200+0.39%
Inovio Pharmaceuticals News
Inovio Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(7.3%)
Inovio Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(7.3%)
Inovio Pharmaceuticals | 424B5: Prospectus
Inovio Pharmaceuticals | 8-K: Current report
Inovio Pharmaceuticals | 8-K: INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Inovio Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Sumner Michael John
Inovio Pharmaceuticals | 8-K: Current report
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Weiner David B.
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Miller Ann Calby
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director YARNO WENDY L
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director BENITO SIMON X
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director DANSEY ROGER D
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zoth Lota S.
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Shepard Jay
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Miller Ann Calby
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director BENITO SIMON X
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer KIES PETER
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Shepard Jay
Inovio Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Humeau Laurent
Analysis
Price Target
No Data
No Data
